Our scientific and project management teams work closely with you to assess feasibility and recommend improvements targeting your desired specifications. Our interactive design process includes comprehensive antibody screening, assay optimization, and feasibility testing. We do the development work so you can get faster answers.

Select up to 20 biomarkers, send in your samples, and receive a full data report and a meeting with our scientific team. See how proteomics can enhance your early cancer detection test with our low-risk sample testing service at LuminexPLORE lab.

Advances in cancer proteomics have helped increase analytical specificity and sensitivity. Case in point is the Oncuria® bladder cancer test from Nonagen Bioscience. Developed using high-quality reagents from R&D Systems, this multiplex immunoassay was shown to have 93% sensitivity and 95% specificity for detecting bladder cancer, with demonstrated consistency across tumor grades and stages.

To move your product closer toward clinical utility, research trials need sensitive and highly reproducible immunoassay systems that can simultaneously interrogate large numbers of targets per sample in a short time. Bio-Techne’s Luminex-based multiplex assays combine high-quality reagents and over 40 years of industry-leading immunoassay experience to create a powerful solution to advance multicancer early detection strategies.

Stringent quality control processes and an extensive in-house selection of antibodies and proteins help ensure the data you generate is accurate and reliable. With more than 300 RUO catalog Luminex analytes, odds are we can accommodate the specific target that will meet your unique research needs. From custom reagents to feasibility assessments, our experienced scientists and project managers work closely with you to develop, adapt, and optimize your early cancer diagnostic test to meet your specific project goals.